IJE Software logoIJEsoft
ServicesPortfolioPricingAboutCase StudyStackNewsBlogPartnerPH NewsMarketsContactGet in touch
← Back to Philippines Business News
Manila Times Business

Getinge Interim Report April-June 2026: Good organic growth, high profitability and strong cash flow

GOTHENBURG, Sweden, July 17, 2026 /PRNewswire/ -- "We delivered a strong quarter both financially and operationally with several important key achievements," says Mattias Perjos, President and CEO of Getinge. Sales in Acute Care Therapies increased in most product categories, and the positive trend in consumables for life-supporting ECLS therapy was maintained. Surgical Workflows continued to display good momentum. The situation in Life Science remains mixed - the high-margin category of Sterile

Context & Analysis

Getinge operates in a sector that directly touches Philippine healthcare delivery. The country’s hospital network, both private and public, relies heavily on imported medical devices and consumables to maintain surgical capacity and critical care standards. When a Swedish medtech firm reports sustained demand for life-support equipment and surgical tools, it signals broader global procurement patterns that eventually filter through Philippine distributors and hospital supply chains.

For Filipino healthcare operators and medical equipment suppliers, this quarter’s performance underscores the resilience of high-margin consumables and acute care solutions. Hospitals here are increasingly upgrading to modular, reusable systems that lower long-term costs, a shift aligned with what international manufacturers are pushing. The Department of Health’s ongoing push for universal healthcare coverage also means public facilities will need to optimize capital spending while maintaining clinical output. That dynamic favors suppliers who can demonstrate strong cash conversion and reliable inventory turnover.

Investors and business owners tracking medtech should watch how global pricing pressures and supply chain adjustments ripple into local import costs. The Philippine peso’s trajectory against European currencies will influence landed prices for hospital procurement, while FDA Philippines clearance timelines remain a practical bottleneck for new device introductions. Additionally, as domestic distributors compete for market share, firms that secure long-term service contracts or bundle consumables with equipment sales will likely capture more stable revenue streams.

The next quarter’s guidance will reveal whether this growth is driven by one-off procurement cycles or sustained demand. Philippine stakeholders should monitor distributor inventory levels, hospital replacement cycles, and any regulatory updates from the FDA on device registration. In a market where healthcare spending remains sensitive to inflation and interest rates, suppliers with disciplined cash management and scalable service models will be best positioned to navigate the coming year.

Analysis by IJE Software — original commentary on the story above.

This is an excerpt. Read the full article at the original source:

Source: manilatimes.net

More from Manila Times Business

CircleHub's New Style Lab Turns Fashion Discovery Into a Live, Real-Time Experience for Designers and Models

1h ago

Mission Therapeutics strikes deal worth up to $292 million for Dimerix Ltd to develop Acute Kidney Injury asset MTX652, sharpens focus on its CNS pipeline

1h ago

Orion Corporation’s financial reporting and Annual General Meeting in 2027

1h ago

EQT Consortium Raises Tender Offer Price for Kakaku.com to JPY 3,450 Per Share

1h ago

Your Daily Briefing

AI business companion — delivered every morning

Markets, PH news, financial insights, and devotionals — curated by AI and sent at 7 AM PHT. Pick your topics below.

Devotionals
Blog Topics
HR & Workforce
Real Estate & Property
News & Markets

1 topic selected